Search
Biodesix Inc
BDSXAdd to Watchlist
21.990USD
-2.510-10.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
174.92MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-10.24%
5 Days
-5.78%
1 Month
+33.27%
6 Months
+240.40%
Year to Date
+223.38%
1 Year
+304.82%
Key Figures
24.520Open
24.730High
62.72KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.79%Turnover Ratio
24.500Prev. Close
21.700Low
1.02MTurnover
LossP/E Static
-101.58P/B
0.00%Div Yield TTM
-35.34%ROA
20.21052wk High
0.85Volume Ratio
-42.93MNet Profit
7.95MShares
-3.9623EPS TTM
0.55Beta
-316.53%ROE
5.00052wk Low
12.37%Amplitude
83.55%Gross Margin
174.92MMarket Cap
7.76Reward/Risk
6.25%Risk Rate
TradingKey Stock Score of Biodesix Inc
Currency: USD Updated: 2026-07-02Key Insights
Biodesix Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biodesix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Biodesix Inc Highlights
StrengthsRisks
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 80.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 88.50M.
Undervalued
The company’s latest PE is -5.55, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.03M shares, increasing 8.73% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
28.750
Target Price
+17.35%
Upside Space
Biodesix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biodesix Inc Info
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Ticker SymbolBDSX
CompanyBiodesix Inc
CEOHutton (Scott)
Websitehttps://www.biodesix.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Biodesix Inc (BDSX)?
The current price of Biodesix Inc (BDSX) is 21.99.
What is the symbol of Biodesix Inc?
The ticker symbol of Biodesix Inc is BDSX.
What is the 52-week high of Biodesix Inc?
The 52-week high of Biodesix Inc is 20.21.
What is the 52-week low of Biodesix Inc?
The 52-week low of Biodesix Inc is 5.00.
What is the market capitalization of Biodesix Inc?
The market capitalization of Biodesix Inc is 174.92M.
Is Biodesix Inc (BDSX) currently rated as Buy, Hold, or Sell?
According to analysts, Biodesix Inc (BDSX) has an overall rating of Buy, with a price target of 28.75.
What is the Earnings Per Share (EPS TTM) of Biodesix Inc (BDSX)?
The Earnings Per Share (EPS TTM) of Biodesix Inc (BDSX) is -4.67.